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I-neb Insight Online is a telemedicine-based patient management system that includes
a multi-access information hub which allows the patient and clinician to access data on
patient adherence to treatment, compliance with correct use and cleaning of the I-neb
AAD System device.
A 13 week handling study of the I-neb Insight Online patient management system
was conducted in forty-nine adult patients with cystic ﬁbrosis (CF). At the end of the
study patients were asked to complete a questionnaire regarding their views on I-neb
Insight Online. We present the results from the 33 questionnaires that were returned by
patients relating to the management of their treatment when using I-neb Insight Online
(Table 1).
Table 1
No. Questions related to management of their treatment. Yes No Note
1 Did you ﬁnd that using Insight Online meant that you used
your I-neb more than previously?
9 25 One patient answered
‘yes’ and ‘no’
2 Were you contacted by a member of the Patient Support
Team (PSP) during the handling study regarding your
treatment data?
30 2
3 Was a problem identiﬁed with your treatment data? 22 9
4 Was this something you were aware of before PSP
contacted you?
18 11
5 Did you ﬁnd the Treatment View data useful? 29 5 One patient answered
‘yes’ and ‘no’
6 Did you ﬁnd the Device View data useful? 26 5
A follow on to Q5 asked ‘Please detail what you found useful about the Treatment View
data’; 13 patients commented it helped them view their use of the device and 8 patients
that it helped them view their treatment times. A follow on to Q6 asked ‘Please detail
what you found useful about the Device View data’; 12 patients commented that they
thought it was useful for monitoring the performance of the mesh.
Patient opinions on using the I-neb Insight Online system were positive and showed
that patients thought its use had positive beneﬁts in a number of different aspects of
their inhalation therapy management.
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I-neb Insight Online is a telemedicine-based patient management system that
facilitates the analysis and presentation of data on a patients’ use of their I-neb
Adaptive Aerosol Delivery (AAD) System. Patients upload treatment data from a
patient logging system (PLS) contained within the I-neb AAD System to a remote
server using their home computer and an internet connection. The data is analyzed
and presented as summary graphs available to patients, their clinicians, and patient
support program (PSP) personnel. If data falls outside expected values the patient
and clinician are alerted so they can adjust the patient’s treatment accordingly. A
13 week handling study was performed to assess use of the I-neb Insight Online
technology in patients with cystic ﬁbrosis (CF). Forty-nine patients were enrolled
(median age 30, range 17.9–50.8 years), and 44 successfully completed the study.
Patients performed 410/607 expected weekly uploads of data and prescription
updates were initiated by either the patient or clinician. Sixty-ﬁve percent of
treatment issues were resolved following contact between PSP personnel and the
patient. Complete prescription and PLS data was available for 38 patients and
showed a mean adherence of 69.4%, a mean compliance of 98.0%, a mean TBM
treatment time of 4.9 min, and a mean TIM treatment time of 2.9 min over the course
of the study. The I-neb Insight Online patient management system provides remote
access to up-to-date adherence, compliance and device data for the identiﬁcation of
treatment issues in order to improve management of inhalation therapy for patients
with CF.
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In the P. aeruginosa PAO1 genome 32% of the genes show no homology to
previously reported sequences and only 6.7% have experimentally demonstrated
functions. Hence, there is plenty of scope for the discovery of new antimicrobial
targets within this organism. To this effect we used a genomic approach to search
the entire P. aeruginosa genome for novel genes required for virulence. We screened
a 60.000 Tn5 mutant library mutants in a P. aeruginosa PAO1 strain tagged with
a lecA::lux-based transcriptional fusion reporting on the expression of the LecA
cytotoxic lectin. All mutants were individually tested for reduced lecA expression,
pyocyanin production, swarming and exo-protease, and for alterations in antibiotic
susceptibility. A total of 273 pleiotropic mutants were further tested for attenuation
in Caenorhabditis elegans and Drosophila melanogaster disease models, and for
reduced cytotoxicity or inﬂammatory response in respiratory cell lines. Some of
those showing the highest attenuation were then tested in the mouse model of acute
infection. In summary, this study has identiﬁed a number of novel genes impacting
on the virulence of P. aeruginosa, which are highly conserved across multiple
sequenced genomes from this organism and which could potentially be exploited
as novel antimicrobial targets.
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Haemoptysis is a common complication of advanced airway disease in cystic
ﬁbrosis (CF). The underlying cause of haemoptysis remains unclear, but studies
suggest that infection plays a major role. In this study we investigated the ability of
proteinases, secreted by three relevant CF pathogens, to degrade ﬁbrinogen (FBG).
Our results show that multiple proteinases secreted by Pseudomonas aeruginosa
and Burkholderia cenocepacia were able to degrade FBG, and that this degradation
differed from that observed when FBG was co-incubated with thrombin. Zymog-
raphy results revealed that FBG degradation by proteinases from Burkholderia
multivorans was less pronounced. In addition, we investigated the effects of various
broad-spectrum and speciﬁc proteinase inhibitors on the ability of the bacterial
proteinases to degrade FBG. Treatment of the bacterial supernatant-FBG co-cultures
with individual inhibitors resulted in partial inhibition of degradation, indicating
that degradation is likely to be due to multiple proteinase species. We then studied
the effects of this degradation on the ability of FBG to form a thrombin-mediated
clot. Our results show that degradation prevents the polymerisation of FBG and is
therefore unable to form ﬁbrin clots in vitro. We are currently assessing the impact
of the bacterial samples on platelet aggregation. These assays will not only provide
functional data but will assist us in identifying speciﬁc bacterial proteins/proteinases
that are involved in the disruption of the clotting process. To date, our results suggest
that bacterial proteinases may contribute to the haemoptysis observed in advanced
CF airway disease by disrupting clot formation.
